Does ARA-290 / cibinetide actually work for neuropathy?
For sarcoidosis-associated small-fiber neuropathy: yes, real Phase 2 data (Heij 2012, Dahan 2013) showed symptom + corneal-nerve-fiber-density improvement at 4 mg / 28 days. For diabetic neuropathy: also yes per Brines 2014, with metabolic-control-improvement bonus. For general peripheral neuropathy or chronic pain: extrapolation, not validated. Phase 3 was never pursued. Not approved.
Last reviewed · Panya.health editorial
Where the evidence actually applies
ARA-290's Phase 2 trial portfolio is unusually focused for a research-chem-space peptide. Heij 2012 (Mol Med) ran 4 mg subcutaneous daily for 28 days in sarcoidosis patients with documented small-fiber neuropathy. Dahan 2013 (Mol Med) extended that to corneal-nerve-fiber-density measurement (a quantitative imaging endpoint for small-fiber neuropathy progression) and showed real density improvement. Brines 2014 (Mol Med) tested it in type 2 diabetes patients with neuropathic symptoms, with both symptom-score and metabolic-marker improvement. All three are the same Leiden University investigator group (Albert Dahan, Monique van Velzen). The trial work is real, the endpoints are quantitative, the n is small (under 50 per trial). Phase 3 was never pursued by Araim Pharmaceuticals; the company restructured before that step.
Why the mechanism is interesting
Erythropoietin (EPO) has long been known to be neuroprotective beyond its hematopoietic role, but EPO itself can't be used at neuro-protective doses because of the red-blood-cell-elevation side effect (clot risk). ARA-290 was engineered to bind only the EPO-receptor / beta-common-receptor heteromer (the 'innate repair receptor') on tissues like nerve and endothelium, not the homodimeric EPOR on red-blood-cell precursors. This separation means the tissue-protective signaling reaches damaged sensory nerve fibres without the hematocrit problem. Mechanism is anti-inflammatory at the nerve-microenvironment level plus stimulation of nerve-fibre regrowth.
When the trade is reasonable
Documented small-fiber neuropathy with a clear etiology (sarcoidosis, diabetes, idiopathic) under the care of a neurologist who can evaluate response. Trial protocol: 4 mg subcutaneous daily for 28 days, then evaluate. Some users extend to 8 to 12 weeks based on response. Reconstitution: standard subcutaneous protocol; the calculator at panya.health/tools/reconstitution-calculator handles the math. The published safety profile is unusually clean for a research peptide; no consistent cardiovascular, hepatic, or hematologic signals across the Leiden trial portfolio.
Where Panya stands
ARA-290 is documented at panya.health/peptide/ara-290 with the full Heij 2012 + Dahan 2013 + Brines 2014 trial portfolio, mechanism, dose, regulatory status. Panya does NOT yet route to vendors for ARA-290 because non-GLP-1 vendor scoring is gated on lawyer review. The compound is rarely synthesized at scale (less common than BPC-157 or TB-500 in research-chem catalogs); supply chain quality is the dominant practical concern. For users with sarcoidosis or diabetic neuropathy specifically, getting evaluated by a neurologist who can assess corneal-nerve-fibre density or other small-fiber-neuropathy quantitative endpoints is the cleaner path than self-treating with research-chem.
Read about this peptide
Related posts
The phrase on every grey-market peptide site. What it actually means, what it does not mean, and why reading it wrong costs people money.
The five things that matter on a COA, the three things that do not, and the one question that separates a serious vendor from a cargo-cult operator.
The clinic route costs more and takes longer. The research-chem route puts more on you. Neither is wrong. Here is how to choose.
People who asked this also asked
The tools behind the answer
The answer for your situation.
The answer above is the general case. The match for your specific profile, region, budget, and urgency comes from our 2-minute quiz. One email, your match, no list.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.